期刊文献+

Oral JS-38,a metabolite from Xenorhabdus sp.,has both anti-tumor activity and the ability to elevate peripheral neutrophils

Oral JS-38,a metabolite from Xenorhabdus sp.,has both anti-tumor activity and the ability to elevate peripheral neutrophils
原文传递
导出
摘要 AIM: JS-38(mitothiolore), a synthetic version of a metabolite isolated from Xenorhabdus sp., was evaluated for its anti-tumor and white blood cell(WBC) elevating activities. METHOD: These anti-proliferative activities were assessed in vitro using a panel of ten cell lines. The anti-tumor activities were tested in vivo using B16 allograft mouse models and xenograft models of A549 human lung carcinoma and QGY human hepatoma in nude mice. The anti-tumor interactions of JS-38 and cyclophosphamide(CTX) or 5-fluorouracil(5-Fu) were studied in a S180 sarcoma model in ICR mice. Specific stimulatory effects were determined on peripheral neutrophils in normal and CTX- and 5-Fu-induced neutropenic mice. RESULTS: The IC50 values ranged from 0.1 to 2.0 μmol·L-1. JS-38(1 μmol·L-1) caused an increase in A549 tumor cell apoptosis. Multi-daily gavage of JS-38(15, 30, and 60 mg?kg-1?d-1) inhibited in vivo tumor progression without a significant effect on body weight. JS-38 additively enhanced the in vivo anti-tumor effects of CTX or 5-Fu. JS-38 increased peripheral neutrophil counts and neutrophil rates in normal BALB/c mice almost as effectively as granulocyte colony-stimulating factor(G-CSF). In mice with neutropenia induced by CTX or 5-Fu, JS-38 rapidly restored neutrophil counts. CONCLUSION: These results suggest that JS-38 has anti-tumor activity, and also has the ability to increase peripheral blood neutrophils. AIM: JS-38(mitothiolore), a synthetic version of a metabolite isolated from Xenorhabdus sp., was evaluated for its anti-tumor and white blood cell(WBC) elevating activities. METHOD: These anti-proliferative activities were assessed in vitro using a panel of ten cell lines. The anti-tumor activities were tested in vivo using B16 allograft mouse models and xenograft models of A549 human lung carcinoma and QGY human hepatoma in nude mice. The anti-tumor interactions of JS-38 and cyclophosphamide(CTX) or 5-fluorouracil(5-Fu) were studied in a S180 sarcoma model in ICR mice. Specific stimulatory effects were determined on peripheral neutrophils in normal and CTX- and 5-Fu-induced neutropenic mice. RESULTS: The IC50 values ranged from 0.1 to 2.0 μmol·L-1. JS-38(1 μmol·L-1) caused an increase in A549 tumor cell apoptosis. Multi-daily gavage of JS-38(15, 30, and 60 mg?kg-1?d-1) inhibited in vivo tumor progression without a significant effect on body weight. JS-38 additively enhanced the in vivo anti-tumor effects of CTX or 5-Fu. JS-38 increased peripheral neutrophil counts and neutrophil rates in normal BALB/c mice almost as effectively as granulocyte colony-stimulating factor(G-CSF). In mice with neutropenia induced by CTX or 5-Fu, JS-38 rapidly restored neutrophil counts. CONCLUSION: These results suggest that JS-38 has anti-tumor activity, and also has the ability to increase peripheral blood neutrophils.
出处 《Chinese Journal of Natural Medicines》 SCIE CAS CSCD 2014年第10期768-776,共9页 中国天然药物(英文版)
基金 supported by the National Natural Science Foundation of China(No.30973639) the Biomedicine Scientific and Technological Projects of Shanghai(#1043 1900700)
关键词 JS-38 (mitothiolore) Xenorhabdus sp. Anti-tumor activity NEUTROPHILS Apoptosis 效率 细胞凋亡 抗肿瘤活性 减少
  • 相关文献

参考文献31

  • 1Scott LM, Lawrence HR, Sebti SM, et al. Targeting protein tyrosine phosphatases for anticancer drug discovery [J]. Curr PharmlDes, 2010, 16 (16): 1843-1862.
  • 2Lemmon MA, Schlessinger J. Cell signaling by receptor- tyrosine kinases [J]. Cell, 2010, 141 (7): 1117-1134.
  • 3Ismael GF, Rosa DD, Mano MS, et al. Novel cytotoxic drugs: old challenges, new solutions [J]. Cancer Treat Rev, 2008, 34 (1): 81-91.
  • 4Chatelut E, Delord JP, Canal E Toxicity patterns of cytotoxic drugs [J]. Invest New Drugs, 2003, 21 (2): 141-148.
  • 5Hartmann JT, Haap J, Kopp HG, et al. Tyrosine kinase inhibitors-a review on pharmacology, metabolism and side effects [J]. Curt Drug Metab, 2009, 10 (5): 470-481.
  • 6Appelbaum F. The clinical use of hematopoietic growth factors [J]. Sere Hematol, 1989, 26 (S3): 7-14.
  • 7Metcalf D. Hematopoietic cytokines [J]. Blood, 2008, 111 (2): 485-491.
  • 8Petrini M, Azzarg A. Lithium in the treatment of neutropenia [J]. Curt Opin Hematol, 2012, 19 (1): 52-57.
  • 9Gaines P, Berliner N, Retinoids in myelopoiesis [J]. J Biol Regul Homeos Ag, 2003, 17 (1): 46-65.
  • 10Kwong YL. Arsenic trioxide in the treatment of haematological malignancies [J]. Expert Opin Drug Saf 2004, 3 (6): 589-597.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部